Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTXNASDAQ:ENTANASDAQ:KRONNASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.51-4.4%$2.04$1.42▼$7.66$89.53M2.811.45 million shs1.26 million shsENTAEnanta Pharmaceuticals$5.05-4.7%$6.41$4.71▼$17.60$107.73M0.47277,463 shs184,618 shsKRONKronos Bio$0.80-4.8%$0.95$0.69▼$1.60$48.78M1.78268,686 shs108,839 shsSOPHSOPHiA GENETICS$3.00-8.8%$3.57$2.70▼$6.28$200.06M1.0168,627 shs29,300 shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-4.43%-9.58%-16.57%-31.36%-69.80%ENTAEnanta Pharmaceuticals-4.72%-13.82%-30.25%-9.50%-69.78%KRONKronos Bio-4.31%-3.03%-15.79%-20.00%-36.51%SOPHSOPHiA GENETICS-8.81%-18.48%-3.23%-7.98%-41.75%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics2.5238 of 5 stars3.53.00.00.00.62.51.3ENTAEnanta Pharmaceuticals3.7358 of 5 stars3.41.00.04.70.04.20.6KRONKronos Bio3.6801 of 5 stars3.25.00.00.03.33.31.3SOPHSOPHiA GENETICS2.8536 of 5 stars3.45.00.00.03.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$14.60866.89% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25241.58% UpsideKRONKronos Bio 2.33Hold$1.63103.13% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80126.67% UpsideCurrent Analyst Ratings BreakdownLatest KRON, SOPH, BDTX, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.003/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.002/11/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.00 ➝ $21.002/11/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$2.26 per shareN/AENTAEnanta Pharmaceuticals$66.59M1.62N/AN/A$5.24 per share0.96KRONKronos Bio$9.85M4.95N/AN/A$2.73 per share0.29SOPHSOPHiA GENETICS$65.17M3.07N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%5/8/2025 (Estimated)ENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)KRONKronos Bio-$112.67M-$1.43N/AN/AN/A-867.66%-64.55%-48.18%5/8/2025 (Estimated)SOPHSOPHiA GENETICS-$78.98M-$0.95N/AN/AN/A-110.71%-55.06%-38.33%5/6/2025 (Estimated)Latest KRON, SOPH, BDTX, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2025Q4 2024KRONKronos Bio-$0.30-$0.43-$0.13-$0.43$1.00 million$2.27 million3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 million2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A5.555.55ENTAEnanta PharmaceuticalsN/A5.475.47KRONKronos BioN/A8.328.32SOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%ENTAEnanta Pharmaceuticals94.99%KRONKronos Bio64.09%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics8.87%ENTAEnanta Pharmaceuticals13.89%KRONKronos Bio24.40%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.66 million51.57 millionOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableKRONKronos Bio10060.97 million45.62 millionOptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableKRON, SOPH, BDTX, and ENTA HeadlinesRecent News About These CompaniesSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateApril 1 at 4:41 AM | marketbeat.comSOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?March 21, 2025 | zacks.comMorgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)March 20, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comSOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTCMarch 18, 2025 | prnewswire.comShort Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 64.4%March 16, 2025 | marketbeat.comSOPHiA GENETICS (SOPH) Receives a Buy from BTIGMarch 12, 2025 | markets.businessinsider.comBaby Sophia from embryo swap will stay with birth parents court rules on appealMarch 11, 2025 | msn.comDistrict Court rules to keep IVF child with birth mother following embryo mix-upMarch 10, 2025 | msn.comCourt overturns ruling that ordered toddler returned to genetic parents following embryo mix-upMarch 10, 2025 | msn.comSophia Genetics price target lowered to $5 from $6 at BTIGMarch 6, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from RBC CapitalMarch 5, 2025 | markets.businessinsider.comSOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comSOPHiA GENETICS Full Year 2024 Earnings: In Line With ExpectationsMarch 5, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comSophia Genetics sees FY25 revenue $72M-$76M, consensus $74.51MMarch 4, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)March 4, 2025 | markets.businessinsider.comSOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 4, 2025 | zacks.comSOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings ResultsMarch 4, 2025 | marketbeat.comSOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | prnewswire.comSOPHiA GENETICS: Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy TestingFebruary 24, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRON, SOPH, BDTX, and ENTA Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.51 -0.07 (-4.43%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.47 -0.04 (-2.65%) As of 09:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.05 -0.25 (-4.72%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$5.04 -0.01 (-0.20%) As of 08:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Kronos Bio NASDAQ:KRON$0.80 -0.04 (-4.76%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.80 0.00 (-0.25%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.SOPHiA GENETICS NASDAQ:SOPH$3.00 -0.29 (-8.81%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$3.26 +0.26 (+8.67%) As of 04/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
